After pausing a trial for a Moderna-partnered cystic fibrosis candidate due to subpar tolerability, Vertex Pharmaceuticals has now decided to discontinue the program entirely. Vertex initially paused ...

It’s been 250 years since the signing of the Declaration of Independence — a milestone that invites not just celebration, but reflection. To illustrate two and a half centuries of U.S. history, Here & ...

A Vertex Pharmaceuticals immunology drug in clinical testing for a rare kidney disease is catching up to others that work in a similar way, but the company contends its therapy can be best in its ...

Vertex Pharmaceuticals said its drug for a rare kidney condition succeeded in a Phase 3 trial. The drug, povetacicept, is a central piece of the company's plan to expand into kidney disease. Vertex ...

I’ve had my Shark Rocket HV301 for seven years, and it has never let me down on hardwood floors, high-pile area rugs, or tile. Recently, I moved into a larger apartment with more furniture, more ...

Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. Vertex said Monday that a drug it secured ...

“Structured products” are proliferating in exchange-traded funds, and defined-outcome ETFs, or “buffer ETFs,” are among the most popular. These ETFs use options to provide an explicit amount of loss ...

Growing experience since the global financial crisis suggests that there is benefit to both advanced and emerging economies from having releasable capital buffers. Building such buffers in normal ...

Here’s what you’ll learn when you read this story: Object Arjuna 2025 PN7 was thought to be a meteorite in an Earthlike orbit, but that is now being questioned. The new hypothesis suggests that 2025 ...

During Vertex’s third-quarter presentation, Chief Commercial Officer Duncan McKechnie cited several numbers that suggest the launch of its long-awaited, non-opioid pain reliever Journavx is trending ...